Meeting
2017 ASCO Annual Meeting
Comparison of somatic mutation profiles from cell free DNA (cfDNA) versus tissue in metastatic urothelial carcinoma (mUC).
Authors
Michael L. Cheng
Memorial Sloan Kettering Cancer Center, New York, NY
Michael L. Cheng , Maha Shady , Catharine Kline Cipolla , Samuel Funt , Maria E. Arcila , Hikmat Al-Ahmadie , Jonathan E. Rosenberg , Dean F. Bajorin , Michael F. Berger , Dana Tsui , David B. Solit , Gopa Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4533)
DOI
10.1200/JCO.2017.35.15_suppl.4533
Abstract #
4533
Poster Bd #
211
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.
First Author: Werner J. Struss
Poster
2018 Genitourinary Cancers Symposium
Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC).
First Author: Bradley Alexander McGregor
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Development and application of an ultra-sensitive ctDNA mutation profiling assay in monitoring therapy response and drug resistance.
First Author: Tom Zhang
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
First Author: Kevin R Reyes